Biodexa Pharmaceuticals Plc SEC filings

Filings

1. 6-KBiodexa Pharmaceuticals PlcBDRX5d

   Biodexa Pharmaceuticals hits 100-patient milestone in FAP trial

   • Enrolled 100 patients in Phase 3 FAP trial
   • Pre-specified futility analysis could occur early next year
   • Database lock potentially by end of next year
2. 424B3Biodexa Pharmaceuticals PlcBDRX5d

   8 structured-note prospectuses

   Securities offering

   Show all 8

   • 424B3Securities offering5d
   • 424B3Securities offering5d
   • 424B3Securities offering5d
   • 424B3Securities offering5d
   • 424B3Securities offering5d
   • 424B3Securities offering5d
   • 424B3Securities offering5d
   • 424B3Securities offering5d
3. 6-KBiodexa Pharmaceuticals PlcBDRXOct 8

   Biodexa Pharmaceuticals announces ADS ratio change

   • ADS ratio changes from 1:50 to 1:400
   • Effective date: October 26, 2026
   • Exchange: 8 old ADSs for 1 new ADS
4. 424B3Biodexa Pharmaceuticals PlcBDRXOct 8

   Biodexa Pharmaceuticals Plc announces share resale

   • 220,421,800 ordinary shares to be resold
   • 4,408,436 American Depositary Shares involved
   • Series P warrants issued in September 2026
5. EFFECTBiodexa Pharmaceuticals PlcBDRXSep 30

   Registration declared effective

6. F-1Biodexa Pharmaceuticals PlcBDRXSep 24

   Securities offering

7. 424B3Biodexa Pharmaceuticals PlcBDRXSep 15

   7 structured-note prospectuses

   Securities offering

   Show all 7

   • 424B3Securities offeringSep 15
   • 424B3Securities offeringSep 15
   • 424B3Securities offeringSep 15
   • 424B3Securities offeringSep 15
   • 424B3Securities offeringSep 15
   • 424B3Securities offeringSep 15
   • 424B3Securities offeringSep 15
8. 6-KBiodexa Pharmaceuticals PlcBDRXSep 15

   Foreign issuer report

9. 424B3Biodexa Pharmaceuticals PlcBDRXSep 11

   7 structured-note prospectuses

   Securities offering

   Show all 7

   • 424B3Securities offeringSep 11
   • 424B3Securities offeringSep 11
   • 424B3Securities offeringSep 11
   • 424B3Securities offeringSep 11
   • 424B3Securities offeringSep 11
   • 424B3Securities offeringSep 11
   • 424B3Securities offeringSep 11
10. 6-KBiodexa Pharmaceuticals PlcBDRXSep 11

    Foreign issuer report

11. SCHEDULE 13G/ABiodexa Pharmaceuticals PlcBDRXAug 14

    Ownership stake disclosure by ARMISTICE CAPITAL, LLC (amended)

    ARMISTICE CAPITAL, LLC, filed by

12. 424B3Biodexa Pharmaceuticals PlcBDRXAug 4

    Securities offering

13. EFFECTBiodexa Pharmaceuticals PlcBDRXAug 4

    Registration declared effective

14. F-1/ABiodexa Pharmaceuticals PlcBDRXJul 30

    Securities offering (amended)

15. 6-KBiodexa Pharmaceuticals PlcBDRXJul 29

    Foreign issuer report

16. F-1Biodexa Pharmaceuticals PlcBDRXJul 15

    Securities offering

17. 6-KBiodexa Pharmaceuticals PlcBDRXJul 9

    Foreign issuer report

18. 424B3Biodexa Pharmaceuticals PlcBDRXJul 1

    6 structured-note prospectuses

    Securities offering

    Show all 6

    • 424B3Securities offeringJul 1
    • 424B3Securities offeringJul 1
    • 424B3Securities offeringJul 1
    • 424B3Securities offeringJul 1
    • 424B3Securities offeringJul 1
    • 424B3Securities offeringJul 1
19. 424B5Biodexa Pharmaceuticals PlcBDRXJul 1

    Securities offering

20. 6-KBiodexa Pharmaceuticals PlcBDRXJun 30

    Foreign issuer report

21. 6-KBiodexa Pharmaceuticals PlcBDRXJun 30

    Foreign issuer report

22. 6-KBiodexa Pharmaceuticals PlcBDRXJun 17

    Foreign issuer report

23. SCHEDULE 13G/ABiodexa Pharmaceuticals PlcBDRXMay 15

    Ownership stake disclosure by ARMISTICE CAPITAL, LLC (amended)

    ARMISTICE CAPITAL, LLC, filed by

24. 6-KBiodexa Pharmaceuticals PlcBDRXMay 14

    Foreign issuer report

25. 424B3Biodexa Pharmaceuticals PlcBDRXApr 2

    2 structured-note prospectuses

    Securities offering

    Show all 2

    • 424B3Securities offeringApr 2
    • 424B3Securities offeringApr 2

Older filings on EDGAR